Rudas Margaretha, Lehnert Martina, Huynh Anh, Jakesz Raimund, Singer Christian, Lax Sigurd, Schippinger Walter, Dietze Otto, Greil Richard, Stiglbauer Wolfgang, Kwasny Werner, Grill Renate, Stierer Michael, Gnant Michael F X, Filipits Martin
Department of Pathology, Medical University of Vienna, Austria.
Clin Cancer Res. 2008 Mar 15;14(6):1767-74. doi: 10.1158/1078-0432.CCR-07-4122.
The objective of our study was to determine the clinical relevance of cyclin D1 expression in hormone receptor-positive breast cancer patients who were treated with tamoxifen-based therapy.
We assessed expression of cyclin D1 in surgical specimens of breast carcinoma by means of immunohistochemistry. Patients had been enrolled in either Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 05 or ABCSG Trial 06 and received tamoxifen as part of their adjuvant treatment. Overall survival and relapse-free survival were analyzed with Cox models adjusted for clinical and pathologic factors.
Cyclin D1 was expressed in 140 of 253 (55%) tumors of ABCSG Trial 05 and in 569 of 948 (60%) tumors of ABCSG Trial 06. Expression of cyclin D1 was associated with poor outcome in both cohorts. Overall survival was significantly shorter in patients with cyclin D1-positive tumors compared with patients with cyclin D1-negative tumors [adjusted hazard ratio (HR) for death (ABCSG Trial 05), 2.47; 95% confidence interval (95% CI), 1.08-5.63; P = 0.03; adjusted HR for death (ABCSG Trial 06), 1.78; 95% CI, 1.36-2.34; P < 0.0001]. Relapse-free survival was also shorter in patients with cyclin D1-positive tumors than in patients with cyclin D1-negative tumors [adjusted HR for relapse (ABCSG Trial 05), 2.73; 95% CI, 1.50-4.96; P = 0.001; adjusted HR for relapse (ABCSG Trial 06), 1.52; 95% CI, 1.14-2.04; P = 0.005].
Cyclin D1 expression is an independent poor prognostic factor in women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen-based therapy.
我们研究的目的是确定细胞周期蛋白D1表达在接受他莫昔芬治疗的激素受体阳性乳腺癌患者中的临床相关性。
我们通过免疫组织化学方法评估乳腺癌手术标本中细胞周期蛋白D1的表达。患者已参加奥地利乳腺癌和结直肠癌研究组（ABCSG）试验05或ABCSG试验06，并接受他莫昔芬作为辅助治疗的一部分。采用经临床和病理因素校正的Cox模型分析总生存期和无复发生存期。
在ABCSG试验05的253例肿瘤中有140例（55%）表达细胞周期蛋白D1，在ABCSG试验06的948例肿瘤中有569例（60%）表达。在两个队列中，细胞周期蛋白D1的表达均与不良预后相关。与细胞周期蛋白D1阴性肿瘤患者相比，细胞周期蛋白D1阳性肿瘤患者的总生存期显著缩短[死亡的校正风险比（HR）（ABCSG试验05），2.47；95%置信区间（95%CI），1.08 - 5.63；P = 0.03；死亡的校正HR（ABCSG试验06），1.78；95%CI，1.36 - 2.34；P < 0.0001]。细胞周期蛋白D1阳性肿瘤患者的无复发生存期也比细胞周期蛋白D1阴性肿瘤患者短[复发的校正HR（ABCSG试验05），2.73；95%CI，1.50 - 4.96；P = 0.001；复发的校正HR（ABCSG试验06），1.52；95%CI，1.14 - 2.04；P = 0.005]。
细胞周期蛋白D1表达是接受辅助他莫昔芬治疗的早期激素受体阳性乳腺癌女性患者的一个独立不良预后因素。
